Small‐for‐size syndrome after living donor liver transplantation: Successful treatment with a transjugular intrahepatic portosystemic shunt

Li Xiao, Fuqiang Li, Bo Wei, Bo Li, Cheng Wei Tang – 18 April 2012 – Small‐for‐size syndrome (SFSS) is a serious complication after living donor liver transplantation (LDLT) that can disrupt liver regeneration and result in hepatic dysfunction. Until now, the treatment options for SFSS after LDLT have been very limited. Here we describe a patient with SFSS after LDLT who was successfully treated with a transjugular intrahepatic portosystemic shunt (TIPS).

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis

Christopher Savard, Erica V. Tartaglione, Rahul Kuver, W. Geoffrey Haigh, Geoffrey C. Farrell, Savitha Subramanian, Alan Chait, Matthew M. Yeh, LeBris S. Quinn, George N. Ioannou – 16 April 2012 – The majority of patients with nonalcoholic fatty liver disease (NAFLD) have “simple steatosis,” which is defined by hepatic steatosis in the absence of substantial inflammation or fibrosis and is considered to be benign.

Is it safe to use a liver graft from a chagas disease–seropositive donor in a human immunodeficiency virus–positive recipient? A case report addressing a novel challenge in liver transplantation

Nicolás Goldaracena, Michelle Mayer Wolf, Emilio Quiñonez, Margarita Anders, Ricardo Mastai, Lucas McCormack – 16 April 2012 – This is the first report presenting a human immunodeficiency virus (HIV)–positive patient with fulminant hepatic failure receiving a liver graft from a Chagas disease–seropositive deceased donor.

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus–coinfected patients

Juan Macías, Juan Berenguer, Miguel A. Japón, José A. Girón‐González, Antonio Rivero, Luis F. López‐Cortés, Ana Moreno, Manuel Márquez, José A. Iribarren, Enrique Ortega, Pilar Miralles, Nicolás Merchante, Juan A. Pineda – 16 April 2012 – Hepatic steatosis (HS) is frequent in human immunodeficiency virus (HIV)‐ and hepatitis C virus (HCV)‐coinfected patients. Antiretroviral therapy (ART) and metabolic alterations could induce HS. However, a protective effect of ART has been reported in a paired biopsy study.

Recruitment mechanisms of primary and malignant B cells to the human liver

Shishir Shetty, Tony Bruns, Christopher J. Weston, Zania Stamataki, Ye H. Oo, Heather M. Long, Gary M. Reynolds, Guy Pratt, Paul Moss, Sirpa Jalkanen, Stefan G. Hubscher, Patricia F. Lalor, David H. Adams – 16 April 2012 – B cells are present within chronically inflamed liver tissue and recent evidence implicates them in the progression of liver disease. In addition, a large proportion of hepatic lymphomas are of B‐cell origin.

Donor‐specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation

Hugo Kaneku, Jacqueline G. O'Leary, Michiko Taniguchi, Brian M. Susskind, Paul I. Terasaki, Göran B. Klintmalm – 16 April 2012 – In a previous study, we found that 92% of patients with chronic rejection had donor‐specific human leukocyte antigen antibodies (DSAs), but surprisingly, 61% of comparator patients without rejection also had DSAs. We hypothesized that immunoglobulin G (IgG) subclasses were differentially distributed between the 2 groups.

Clostridium difficile infection in hospitalized liver transplant patients: A nationwide analysis

Muhammad Ali, Ashwin N. Ananthakrishnan, Shahryar Ahmad, Nilay Kumar, Gagan Kumar, Kia Saeian – 14 April 2012 – The incidence of Clostridium difficile infection (CDI) is increasing among hospitalized patients. Liver transplantation (LT) patients are at higher risk for acquiring CDI. Small, single‐center studies (but no nationwide analyses) have assessed this association. We used the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project (2004‐2008) for this retrospective, cross‐sectional study.

Subscribe to